jaktinib · Zepuping

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Severe alopecia areata in adults (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Latest reported trial: NCT05526222 · Phase 3 · met primary endpoint · grade pending

track record: Partial signal

Also in development:Myelofibrosis · Phase 3 · investigational in the USAlopecia Areata · Phase 3 · investigational in the US

Also approved (2)
CNProduct first approved 2025

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Alopecia Areata
NCT05255237 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-03-25 – 2024-06-28 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT05676242 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-01-11 – 2026-03-12 · Atopic Dermatitis
What this study did
Myelofibrosis
Other / comorbidity
NCT05861128 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-11-10 – 2026-03-04 · Ankylosing Spondylitis
What this study did
NCT05861102 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-07-20 – 2025-06-09 · Ankylosing Spondylitis
What this study did
Phase 2 (18)
Alopecia Areata
NCT04034134 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2019-11-18 – 2021-11-26 · Alopecia Areata
What this study did
Atopic Dermatitis
Myelofibrosis
NCT07471503 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-16 – 2030-04-01 · Myelofibrosis (MF), HSCT
What this study did
NCT07938580 · Peking Union Medical College Hospital
2026-11 – 2029-12 · Myelofibrosis
What this study did
NCT04851535 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-07-28 – 2022-11-01 · Myelofibrosis
What this study did
NCT04217993 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-01-07 – 2022-08-03 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
What this study did
NCT03886415 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2019-01-08 – 2021-02-02 · Myelofibrosis
What this study did
Other / comorbidity
NCT07157306 · Tianjin Medical University Cancer Institute and Hospital
2025-09-10 – 2028-01-01 · Hepatocellular Carcinoma
What this study did
NCT07197112 · Ruijin Hospital
2025-10-01 – 2027-12-01 · Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
What this study did
NCT07185633 · Bin Gu
2026-01-01 – 2027-10-01 · aGVHD
What this study did
NCT04971551 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-12 – 2025-07 · Acute Graft-Versus-Host Disease
What this study did
NCT05686629 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-04 – 2025-03 · Novel COVID-19-Infected Pneumonia
What this study did
NCT05688839 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-04 – 2025-03 · Novel COVID-19-Infected Pneumonia
What this study did
NCT05672888 · First Affiliated Hospital of Zhejiang University
2023-03 – 2024-05 · COVID-19 Pneumonia
What this study did
NCT05702788 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-09 – 2024-04-23 · COVID-19, Pneumonia
What this study did
NCT04612699 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-03-11 – 2022-08-15 · Moderate-to-Severe Plaque Psoriasis
What this study did
NCT04507659 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-12-01 – 2022-08-02 · Ankylosing Spondylitis
What this study did
NCT04312594 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-09-08 – 2022-06-09 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1/2 (12)
Alopecia Areata
NCT04445363 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-08-12 – 2024-12-01 · Alopecia Areata(AA)
What this study did
Atopic Dermatitis
NCT04435392 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-10-14 – 2022-09-08 · Atopic Dermatitis
What this study did
Myelofibrosis
NCT04866056 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-09-30 – 2022-06-10 · Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Myelofibrosis
What this study did
Other / comorbidity
NCT07012304 · Yujun DONG
2025-06-30 – 2029-02-28 · Chronic Graft Versus Host Disease
What this study did
NCT07476872 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-16 – 2028-11-01 · cGVHD, HSCT
What this study did
NCT07885228 · Nanfang Hospital, Southern Medical University
2026-10-10 – 2028-06-10 · Acute Graft vs Host Disease
What this study did
NCT07285889 · First Affiliated Hospital of Zhejiang University
2025-12-03 – 2027-12-31 · Acute Graft Versus Host Disease
What this study did
NCT07142837 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09 – 2027-12 · Advanced Solid Tumor
What this study did
NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09-23 – 2027-12 · Cervical Cancer
What this study did
NCT06903377 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-23 – 2027-05 · Non-small Cell Lung Cancer
What this study did
NCT06883526 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-16 – 2027-05 · Lymphoma
What this study did
Phase 1 (8)
Myelofibrosis
NCT05279001 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-07-01 – 2025-11-30 · Myelofibrosis
What this study did
NCT06132243 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-11-29 – 2023-12-20 · Myelofibrosis
What this study did
Other / comorbidity
NCT07565597 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-05-12 – 2027-03 · Healthy
What this study did
NCT06193148 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-03-19 – 2024-06-18 · Healthy Participants
What this study did
NCT04993404 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-08-27 – 2022-09-19 · Hepatic Insufficiency, Healthy Subjects
What this study did
NCT05150717 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-01-04 – 2022-01-30 · Healthy Adult Male Volunteers
What this study did
NCT06246695 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-10-27 – 2022-01-12 · Healthy Volunteers
What this study did
NCT03314402 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2017-09-28 – 2018-09-27 · Healthy Volunteers
What this study did
Early phase / not applicable (4)
Myelofibrosis
NCT07440654 · Nanfang Hospital, Southern Medical University
2026-03-01 – 2029-12-01 · aGVHD Prophylaxis
What this study did
NCT07904871 · First Affiliated Hospital of Zhejiang University
2026-11-01 – 2029-11-01 · Myelofibrosis, Primary Myelofibrosis (PMF), Secondary Myelofibrosis
What this study did
Other / comorbidity
NCT07454226 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-30 – 2030-03-01 · Ph-Like, Acute Lymphoblastic Leukemia
What this study did
NCT07445893 · Duan Minghui
2026-04-02 – 2028-12-30 · Polycythemia Vera (PV)
What this study did

Competitive landscape

This drug's own stage for Alopecia Areata: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Jaktinib (Zepuping): this drugPhase 3Small moleculeJAK1/2/3Partial signal
NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13).
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphaPartial signal
NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison.
RezpegaldesleukinPhase 2Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zepuping (jaktinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicablePolycythemia Vera (PV)Recruiting
Est. primary completion 2026-12-30 · NCT07445893 · CT.gov ↗
What to watch
2027 (12)
January 2027 (1)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-01-01 · NCT07157306 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1HealthyActive not recruiting
Est. primary completion 2027-02 · NCT07565597 · CT.gov ↗
What to watch
Phase 2Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host DiseaseNot yet recruiting
Est. primary completion 2027-02-01 · NCT07197112 · CT.gov ↗
What to watch
Phase 1/2Chronic Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-02-28 · NCT07012304 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Non-small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT06903377 · CT.gov ↗
What to watch
Phase 1/2LymphomaRecruiting
Est. primary completion 2027-04 · NCT06883526 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Acute Graft vs Host DiseaseNot yet recruiting
Est. primary completion 2027-06-10 · NCT07885228 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2Cervical CancerRecruiting
Est. primary completion 2027-08 · NCT07080216 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2027-10 · NCT07142837 · CT.gov ↗
What to watch
Phase 2aGVHDRecruiting
Est. primary completion 2027-10-01 · NCT07185633 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2cGVHD, HSCTNot yet recruiting
Est. primary completion 2027-11-01 · NCT07476872 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Acute Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT07285889 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Early phase / not applicablePh-Like, Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT07454226 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2028-10-28 · NCT07883382 · CT.gov ↗
What to watch
November 2028 (1)
Early phase / not applicableMyelofibrosisNot yet recruiting
Est. primary completion 2028-11-01 · NCT07904871 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2MyelofibrosisNot yet recruiting
Est. primary completion 2028-12 · NCT07938580 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 2MyelofibrosisNot yet recruiting
Est. primary completion 2029-04-01 · NCT07471503 · CT.gov ↗
What to watch
September 2029 (1)
Early phase / not applicableMyelofibrosisNot yet recruiting
Est. primary completion 2029-09-01 · NCT07440654 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 April 2026Topline resultZGJAK025 (NCT05526222) Phase 3 in moderate-to-severe atopic dermatitis met its primary endpoints
Suzhou Zelgen Biopharmaceuticals Co., Ltd. · Source ↗
21 October 2025Topline resultZGJAK029 (NCT05861102) Phase 3 in active ankylosing spondylitis met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) · Source ↗
13 June 2024Topline resultZGJAK018 (NCT05051761) Phase 3 in severe alopecia areata met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) · Source ↗